Patents Assigned to Universite de Montpellier
  • N-hydroxybenzamides as HDAC inhibitors for the treatment of parasitic diseases
    Patent number: 10106493
    Abstract: Compounds of formula wherein n is 0, 1 or 2; X is and Ar is a benzyl substituted at the meta position by a C1 to C8 alkoxy group, or a pharmaceutically acceptable salt thereof, for treating, preventing or inhibiting a parasitic disease, such as toxoplasmosis, in a subject are provided. Methods for preparing the compounds are also presented.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: October 23, 2018
    Assignees: INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (I.R.D.), UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Denis Sereno, Gilles Labesse, Jean-Francois Alexandre Guichou, Corinne Loeuillet, Deborah Isabelle Garcia, Stephane Delbecq
  • Methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject
    Patent number: 10105452
    Abstract: The present invention relates to methods and pharmaceutical compositions for expressing a polynucleotide of interest in the retinal pigment epithelium of a subject. In particular, the present invention relates to a method for selectively expressing a polynucleotide of interest in the retinal pigment epithelium in an eye of a subject in need thereof comprising the step of transducing the retinal pigment epithelium with an amount of a rAAV2/5 vector containing the polynucleotide of interest.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 23, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE DE MONTPELLIER
    Inventors: Christian Hamel, Vasiliki Kalatzis, Marie Pequignot, Nicolas Cereso
  • FLT3 receptor antagonists for the treatment or the prevention of pain disorders
    Patent number: 10106798
    Abstract: The present invention relates to FLT3 receptor antagonists or inhibitors of FLT3 receptor gene expression for the treatment or the prevention of pain disorders.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 23, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), UNIVERSITE DE MONTPELLIER
    Inventor: Jean Valmier
  • Process for preparing synthesis intermediates using products of natural origin and use of the intermediates obtained
    Patent number: 10099987
    Abstract: Disclosed is a process for preparing a product of formula I: wherein the reaction is catalyzed both by thiamine or a thiamine salt and by ascorbic acid in a form which is free or salified or an organic acid salt of an alkaline metal, preferably sodium acetate, potassium tartrate, sodium succinate, or a reductone, preferably 2-hydroxypropanedial or 2,3-dihydroxycyclopent-2-ene-1-one in an organic solvent.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: October 16, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Claude Grison, Vincent Escande, Andrii Stanovych
  • Hydrosilane/Lewis acid adduct, particularly aluminum, iron, and zinc, method for preparing same, and use of said same in reactions for reducing carbonyl derivatives
    Patent number: 10099986
    Abstract: Disclosed is an adduct between a Lewis acid, preferably aluminum trichloride, iron trichloride, or zinc dichloride, and a hydrosilane;—a method for preparing same; and a method for for reducing, particularly, an aldehyde, a ketone, an ?,?-unsaturated ketone, an imine, or an ?,?-unsaturated imine.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: October 16, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Claude Grison, Vincent Escande
  • RECEPTOR-BINDING DOMAINS LIGANDS FOR THE DETECTION, DIAGNOSIS AND TREATMENT OF PANCREATIC CANCER
    Publication number: 20180280549
    Abstract: Disclosed are methods for diagnosing pancreatic cancer, including measuring the expression level of ASCT1 and/or ASCT2 and/or XPR1. Also disclosed is a RBD ligand coupled to at least one contrast agent, that may be used as a probe for medical imaging.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 4, 2018
    Applicants: METAFORA BIOSYSTEMS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
    Inventors: Jawida TOUHAMI, Guangqi E, Donatella GIOVANNINI, Bruno ROBERT, Samuel SEVESTRE, Muriel BUSSON, Jean-Luc BATTINI, Vincent PETIT, Marc SITBON
  • Continuous heat treatment method for an electrically conductive fluid
    Patent number: 10082338
    Abstract: A method is provided for heating an electrically conductive fluid, including steps of: (i) circulating the fluid in a circuit from an inlet to an outlet, through an inlet path of the circuit in which the fluid flows in a first average direction and an outlet path of the circuit in which the fluid flows in a second average direction substantially opposite to the first direction; (ii) subjecting the fluid to a specific ohmic heating while the fluid flows through the outlet path; and (iii) transferring heat from the fluid flowing through the outlet path to the fluid flowing through the inlet path by thermal conduction through an at least partially first electrically insulated partition wall. An associated heating device is also provided.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: September 25, 2018
    Assignees: UNIVERSITE DE MONTPELLIER, EMMEPIEMME
    Inventors: Jean-Pierre Lucien Joseph Pain, Stephanie Roux, Mario Massa
  • Targeting of human interferon antagonists
    Patent number: 10072059
    Abstract: The present invention relates to a fusion protein, comprising a cytokine antagonist and a targeting moiety, preferably an antibody or anti-body like molecule. In a preferred embodiment, the cytokine antagonist is a modified cytokine which binds to the receptor, but doesn't induce the receptor signalling. The invention relates further to a fusion protein according to the invention for use in treatment of cancer and immune- or inflammation-related disorders.
    Type: Grant
    Filed: July 6, 2017
    Date of Patent: September 11, 2018
    Assignees: VIB VZW, UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER, CENTRE HOSPITALIER REGIONAL UNIVERSITAIRE DE MONTPELLIER
    Inventors: Jan Tavernier, Lennart Zabeau, Gilles Uze, Franciane Paul, Yann Bordat, Genevieve Garcin
  • Supported membrane functionalized with hexa- and octacyanometallates, process for the preparation thereof and separation process using same
    Patent number: 10068676
    Abstract: A supported membrane is provided comprising an inorganic, solid porous filtration membrane supported by an inorganic, solid porous support, said supported membrane comprising nanoparticles of a metal coordination polymer with CN ligands comprising Mn+ cations, where M is a transition metal and n is 2 or 3; and Alk+y[M?(CN)m]x? anions where Alk is an alkaline metal, y is 0, 1 or 2, M? is a transition metal, x is 3 or 4, and m is 6 or 8; said Mn+ cations of the coordination polymer being bound through an organometallic or coordination bond to an organic group of an organic graft chemically attached to the surface of the filtration membrane, inside the pores of the filtration membrane, and optionally inside the pores of the support. The supported membrane may be used in a process for separating at least one metal cation and solid particles from a liquid medium containing the same.
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: September 4, 2018
    Assignees: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CERAMIQUES TECHNIQUES ET INDUSTRIELLES (CTI), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE MONTPELLIER
    Inventors: Agnes Grandjean, Yves Barre, Eric Louradour, Didier Dhaler, Yannick Guari, Joulia Larionova
  • FLT3 receptor antagonists
    Patent number: 10065937
    Abstract: The invention pertains to novel FLT3 receptor antagonists of general formula (1). The compounds are useful for the treatment or the prevention of pain disorders, cancer and autoimmune diseases.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 4, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE STRASBOURG
    Inventors: Jean Valmier, Jean-Philippe Leyris, Didier Rognan, Martine Schmitt
  • Methods for selecting competent oocytes and competent embryos with high potential for pregnancy outcome
    Patent number: 10059994
    Abstract: The present invention relates to a method for selecting a competent oocyte or a competent embryo by determining the expression level of specific microRNA species in a body fluid or in cumulus cells.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: August 28, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), UNIVERSITE DE MONTPELLIER 1, CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER
    Inventors: Samir Hamamah, Said Assou
  • P/METAL-N-C HYBRID CATALYST
    Publication number: 20180241047
    Abstract: A P/Metal-N—C hybrid catalyst that includes at least one nitrogen-doped carbonaceous matrix onto which at least one non-precious transition metal is covalently bonded and that includes at least one partially oxidised precious transition metal P of which the weight percentage is less than or equal to 4.0%, and preferably less than or equal to 2.0%, relative to the mass of the P/Metal-N—C hybrid catalyst. Further, an electrochemical device that includes such a device, for example a fuel cell with a polymer electrolyte membrane.
    Type: Application
    Filed: September 12, 2016
    Publication date: August 23, 2018
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITÉ DE MONTPELLIER
    Inventors: Anna SCHUPPERT, Frédéric JAOUEN, Deborah JONES
  • COMPOUNDS USEFUL FOR TREATING CANCER
    Publication number: 20180222888
    Abstract: The present invention relates to a compound of formula (I): wherein A and A? independently represent a phenylene group or a pyridylene group; R2 is a hydrogen atom or a (C1-C4)alkyl group; R3 is a 2-pyridyl group, 3-pyridyl group, a 4-pyridyl group, a 2-pyrimidinyl group, a 4-pyrimidinyl group or a 5-pyrimidinyl group; R4 is a carbonyl group or a sulfonyl group; and R5 is a —NH—(CH2)a—NR6R7 group or a 4-methylpiperazinyl group, with a being an integer from 1 to 4, R6 and R7 representing independently a (C1-C4)alkyl group, or R6 and R7 together with the nitrogen atom to which they are linked forming a heterocycle group which is chosen among a 4-methylpiperazinyl group, a morpholino group, a pyrrolidinyl group and a piperidino group; or any one of its pharmaceutically acceptable salt.
    Type: Application
    Filed: April 5, 2018
    Publication date: August 9, 2018
    Applicants: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Pierre ROUX, Florence MAHUTEAU, Romain NAJMAN, Gilles GADEA, Jamal TAZI, Didier SCHERRER, Carsten BROCK, Nathalie CAHUZAC
  • Flavonoid derivative compounds and method for preparing same by depolymerization of condensed tannins
    Patent number: 10030009
    Abstract: A compound of general formula (I) in which R1, R2, R3 and R5, identical or different, each represent a hydrogen atom or a hydroxyl group, optionally protected by a protecting group. R4 represents a hydrogen atom or an —OR7 group, in which R7 represents a hydrogen atom, a protecting group or a gallate group. R6 represents a hydroxyl group, optionally protected by a protecting group. R?1, R?2, R?3 and R?4, identical or different, each represent a hydrogen atom or a substituent not comprising a mesomeric electron withdrawing group conjugated with the furan ring. A substituent from R?1, R?2, R?3 and R?4 representing the covalent bond with the pyran ring or one of the salts of same. A method for obtaining such a compound includes a step of depolymerization of condensed tannins in the presence of an acid by means of a nucleophile derived from furan.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: July 24, 2018
    Assignees: INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, CENTRE INTERNATIONAL D'ETUDES SUPERIEURES EN SCIENCES AGRONOMIQUES, UNIVERSITE DE MONTPELLIER 1
    Inventors: Laurent Roumeas, Hélène Fulcrand, Chahinez Aouf, Eric Dubreucq
  • NEW HYDROGELS HAVING A SILYLATED STRUCTURE, AND METHOD FOR OBTAINING SAME
    Publication number: 20180200408
    Abstract: The present invention relates to hydrogels prepared using silylated organic molecules (such as silylated biomolecules), a method for obtaining same, and uses thereof.
    Type: Application
    Filed: July 7, 2016
    Publication date: July 19, 2018
    Applicants: Universite de Montpellier, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Jean Martinez, Ahmad Mehdi, Gilles Subra, Said Jebors, Cécile Echalier
  • Compounds useful for treating AIDS
    Patent number: 10017498
    Abstract: A compound having the following formula or a pharmaceutically acceptable salt thereof: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NR1R2 group, a (C1-C3)fluoroalkoxy group, a —NO2 group, a phenoxy group, or a (C1-C4)alkoxy group, R1 and R2 are independently a hydrogen atom or a (C1-C3)alkyl group, R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, or a (C1-C4)alkoxy group, R? is a hydrogen atom or a (C1-C4)alkyl group, n is 1, 2, or 3, and n? is 1 or 2.
    Type: Grant
    Filed: July 1, 2015
    Date of Patent: July 10, 2018
    Assignees: ABIVAX, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE, UNIVERSITE DE MONTPELLIER
    Inventors: Jamal Tazi, Florence Mahuteau, Romain Najman, Didier Scherrer, Noelie Campos, Aude Garcel
  • FLUOROETHER UNIT-BASED THERMOSTABLE, LOW-TG AND THERMOSETTING CROSS-LINKED MATERIALS
    Publication number: 20180186934
    Abstract: The present invention relates to a cross-linkable composition comprising: i) a fluorinated ?,?-bis(propargyl) oligomer of formula (I): in which m is 1 to 100, e.g. 1 to 93, n is 2 to 150, e.g. 1 to 128, p is 0 to 2 preferably 0 or 1.75, and, n, m and p are selected such that the fluorinated ?,?-bis(propargyl) oligomer of formula (I) has a number average molar mass Mn of 400 to 25000; ii) a cross-linking agent comprising at least three azide-N3 groups; and iii) optionally, a fluorinated oligomer comprising two terminal azide-N3 or fluorinated ?,?-bis(azide) oligomer groups. The invention also relates to a material comprising the click chemistry reaction product of the cross-linkable composition of the invention, to a method for preparing said material and to the uses thereof.
    Type: Application
    Filed: July 1, 2016
    Publication date: July 5, 2018
    Applicants: SAFRAN ELECTRICAL & POWER, UNIVERSITE DE MONTPELLIER, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Mathieu CHARLAS, Donatien Henri Edouard MARTINEAU, Gerald Pierre Maurice LOPEZ, Jean-Pierre HABAS, Bruno AMEDURI
  • Lipophenol compounds and uses thereof
    Patent number: 10011620
    Abstract: The present invention relates to a compound of formula (I) wherein: i is 0 or 1; j is 0 or 1; k is 0 or 1; R1 and R2 are in particular H, (C1-C12)alkyl, or a group of formula C(O)R; R is a, linear or branched, alkyl radical, comprising at least 19 carbon atoms; R3 is H and k=0 when j=1; or, when j=0, R3 is —C(O)R or -L-C(O)R; L, U and L? are linkers; wherein, when j=0, at least one of the groups R1; R2 and R3 comprises a radical R.
    Type: Grant
    Filed: April 24, 2015
    Date of Patent: July 3, 2018
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER, UNIVERSITE D'AUVERGNE, UNIVERSITE DE MONTPELLIER
    Inventors: Philippe Brabet, David Cia, Laurent Guillou, Christian Hamel, Claire Vigor, Thierry Durand, Céline Crauste, Joseph Vercauteren
  • Method for determining radiosensitivity
    Patent number: 10001491
    Abstract: The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 19, 2018
    Assignees: Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: David Azria, Jerome Lacombe, Jerome Solassol, Alain Mange
  • Long base inclinometer with optical measurement
    Patent number: 9995579
    Abstract: A tiltmeter to measure a variation in inclination of a structure from a given starting position. The tiltmeter has two pots, each pot contains an identical volume and identical height of an identical liquid. A communication device connects the two pots and allows the liquid to flow between the two pots by the principle of communicating vessels. Two optical measuring devices are provided, one optical measuring device per pot. Each optical measuring device measures a variation in height of the level of liquid in the associated pot. The optical measuring devices are fiber optic devices coupled to a common light source.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: June 12, 2018
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIC, UNIVERSITE DE MONTPELLIER
    Inventor: Frederick Boudin